Alissa Hsu Lynch Net Worth

The estimated Net Worth of Alissa Hsu Lynch is at least $92.3 Mille dollars as of 29 November 2022. Alissa Lynch owns over 1,700 units of Pulmonx Corp stock worth over $92,303 and over the last 3 years Alissa sold LUNG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alissa Lynch LUNG stock SEC Form 4 insiders trading

Alissa has made over 1 trades of the Pulmonx Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently Alissa bought 1,700 units of LUNG stock worth $9,367 on 29 November 2022.

The largest trade Alissa's ever made was buying 1,700 units of Pulmonx Corp stock on 29 November 2022 worth over $9,367. On average, Alissa trades about 425 units every 0 days since 2021. As of 29 November 2022 Alissa still owns at least 11,910 units of Pulmonx Corp stock.

You can see the complete history of Alissa Lynch stock trades at the bottom of the page.

What's Alissa Lynch's mailing address?

Alissa's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Pulmonx Corp

Over the last 4 years, insiders at Pulmonx Corp have traded over $195,808,760 worth of Pulmonx Corp stock and bought 107,681 units worth $1,883,657 . The most active insiders traders include Scientific Corp Boston, Thomas William Burns e Glendon E. Iii French. On average, Pulmonx Corp executives and independent directors trade stock every 13 days with the average trade being worth of $393,258. The most recent stock trade was executed by Geoffrey Beran Rose on 3 September 2024, trading 4,586 units of LUNG stock currently worth $30,726.

What does Pulmonx Corp do?

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Complete history of Alissa Lynch stock trades at Pulmonx Corp

Pulmonx Corp executives and stock owners

Pulmonx Corp executives and other stock owners filed with the SEC include:

• Glendon E. French,
  CEO, Pres & Director
• Geoffrey Beran Rose,
  Chief Commercial Officer
• David A. Lehman,
  Gen. Counsel & Sec.
• John B. McKune,
  VP & Controller
• Jérôme Erath,
  Sr. VP & GM of Europe Middle-East & Africa
• Marcee M. Maroney,
  VP of Marketing
• Lauren Cristina,
  VP of Fin. & Admin. (U.S.)
• Sri Radhakrishnan,
  Chief Technical Officer
• Dr. Derrick Sung,
  Chief Financial Officer
• Mehul Joshi,
  Chief Financial Officer & PAO
• Alissa Hsu Lynch,
  Director
• Richard Ferrari,
  
• Staffan Lindstrand,
  Director
• Thomas William Burns,
  
• Dana G Jr. Mead,
  
• Scientific Corp Boston,
  10% owner
• Steven S. Williamson,
  PRESIDENT AND CEO
• Derrick Sung,
  Chief Financial Officer
• Geoffrey Beran Rose,
  CHIEF COMMERCIAL OFFICER
• Glendon E. Iii French,
  
• John Mc Kune,
  INTERIM CFO
• David Aaron Lehman,
  GENERAL COUNSEL
• Daniel P Florin,
  
• Georgia Melenikiotou,
  
• Tiffany Sullivan,